

## Eisai Co Ltd (4523) - Financial and Strategic SWOT Analysis Review

URL:	<a href="https://marketpublishers.com/r/EA84063DD6AEN.html">https://marketpublishers.com/r/EA84063DD6AEN.html</a>
Date:	August 8, 2018
Pages:	64
Price:	US\$ 125.00
ID:	EA84063DD6AEN

Eisai Co Ltd (4523) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

### Highlights

Eisai Co Ltd (Eisai) is a pharmaceutical company that undertakes the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) drugs, prescription medicines and generics. The company's franchise areas in research include neurology and oncology. Eisai's major products include Pariet/AcipHex (proton pump inhibitor); Aricept, an anti-Alzheimer's agent; Halaven, a novel anti-cancer agent; Fycompa, an anti-epileptic and peripheral neuropathy treatment, among others. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

### Eisai Co Ltd Key Recent Developments

Jul 27,2018: AAIC 2018 introduces first clinical trial showing intensive blood pressure therapy reduces new cases of mild cognition and dementia

Jul 19,2018: PhoenixBio provides results from studies using PXB-Mouse and PXB-cells being presented at

ISSX 2018

Jul 18,2018: Eisai supports relief efforts for flooding in western Japan

Jul 04,2018: Eisai Listed For 17th Consecutive Year In FTSE4GOOD Index Series, An Index For Socially Responsible Investment

Jun 13,2018: Eisai To Establish New Research Facility "Eisai Center For Genetics Guided Dementia Discovery" In Cambridge, Massachusetts In The United States

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Table of Content

### SECTION 1 - ABOUT THE COMPANY

Eisai Co Ltd - Key Facts  
Eisai Co Ltd - Key Employees  
Eisai Co Ltd - Key Employee Biographies  
Eisai Co Ltd - Major Products and Services  
Eisai Co Ltd - History  
Eisai Co Ltd - Company Statement  
Eisai Co Ltd - Locations And Subsidiaries  
Head Office

Other Locations & Subsidiaries  
Joint Venture

## **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
Eisai Co Ltd - Business Description  
Product Category: Neurology Products  
Overview  
Performance  
Product Category: Oncology Products  
Overview  
Performance  
Product Category: Others  
Performance  
Product Category: Americas Pharmaceutical Business  
Overview  
Performance  
Product Category: Asia and Latin America Pharmaceutical Business  
Overview  
Performance  
Product Category: China Pharmaceutical Business  
Overview  
Performance  
Product Category: EMEA Pharmaceutical Business  
Overview  
Performance  
Product Category: Japan Pharmaceutical Business  
Overview  
Performance  
Product Category: Other Business  
Overview  
Performance  
R&D Overview  
Eisai Co Ltd - Corporate Strategy  
Eisai Co Ltd - SWOT Analysis  
SWOT Analysis - Overview  
Eisai Co Ltd - Strengths  
Eisai Co Ltd - Weaknesses  
Eisai Co Ltd - Opportunities  
Eisai Co Ltd - Threats  
Eisai Co Ltd - Key Competitors

## **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

## **SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018  
Eisai Co Ltd, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Jul 27, 2018: AAIC 2018 introduces first clinical trial showing intensive blood pressure therapy reduces new cases of mild cognition and dementia  
Jul 19, 2018: PhoenixBio provides results from studies using PXB-Mouse and PXB-cells being presented at ISSX 2018  
Jul 18, 2018: Eisai supports relief efforts for flooding in western Japan  
Jul 04, 2018: Eisai Listed For 17th Consecutive Year In FTSE4GOOD Index Series, An Index For Socially Responsible Investment  
Jun 13, 2018: Eisai To Establish New Research Facility “Eisai Center For Genetics Guided Dementia Discovery” In Cambridge, Massachusetts In The United States  
Jun 13, 2018: Eisai To Establish New Research Facility “Eisai Center For Genetics Guided Dementia Discovery” In Cambridge, Massachusetts In The United States  
Jun 13, 2018: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research Using Novel Nucleic Acid Synthesis And Delivery Technologies Concluded  
Feb 26, 2018: Launch of Dementia Support Insurance to Provide for Dementia in Japan  
Feb 20, 2018: EISAI Certified In 2018 As Outstanding Health And Productivity Management Organization (WHITE 500)  
Feb 20, 2018: EISAI Certified In 2018 As Outstanding Health And Productivity Management Organization (WHITE 500)

## **SECTION 6 – APPENDIX**

Methodology  
Ratio Definitions  
About GlobalData  
Contact Us  
Disclaimer

## **LIST OF TABLES**

Eisai Co Ltd, Key Facts  
Eisai Co Ltd, Key Employees  
Eisai Co Ltd, Key Employee Biographies  
Eisai Co Ltd, Major Products and Services  
Eisai Co Ltd, History  
Eisai Co Ltd, Subsidiaries  
Eisai Co Ltd, Joint Venture  
Eisai Co Ltd, Key Competitors  
Eisai Co Ltd, Ratios based on current share price  
Eisai Co Ltd, Annual Ratios  
Eisai Co Ltd, Annual Ratios (Cont.1)  
Eisai Co Ltd, Annual Ratios (Cont.2)  
Eisai Co Ltd, Interim Ratios  
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018  
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018  
Eisai Co Ltd, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios

Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## **LIST OF FIGURES**

Eisai Co Ltd, Performance Chart (2014 - 2018)  
Eisai Co Ltd, Ratio Charts  
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018  
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

## **COMPANIES MENTIONED**

Astellas Pharma Inc  
Chugai Pharmaceutical Co Ltd  
Daiichi Sankyo Inc  
Mochida Pharmaceutical Co Ltd  
Nippon Kayaku Co Ltd  
Ono Pharmaceutical Co Ltd  
Takeda Pharmaceutical Co Ltd

### I would like to order:

**Product name:** Eisai Co Ltd (4523) - Financial and Strategic SWOT Analysis Review  
**Product link:** <https://marketpublishers.com/r/EA84063DD6AEN.html>  
**Product ID:** EA84063DD6AEN  
**Price:** US\$ 125.00 (Single User License / Electronic Delivery)

*If you want to order Corporate License or Hard Copy, please, contact our Customer Service: [office@marketpublishers.com](mailto:office@marketpublishers.com)*

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/EA84063DD6AEN.html>

### To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
E-mail:  
Company:  
Address:  
City:  
Zip/Post Code:  
Country:  
Tel:  
Fax:  
Your message:

\* All fields are required

Customer Signature \_\_\_\_\_

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at [https://marketpublishers.com/docs/terms\\_conditions.html](https://marketpublishers.com/docs/terms_conditions.html)

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**